trial

STEP-ED: Reducing Duration of Untreated Psychosis and Its Impact in the U.S.

NCTId NCT02069925
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 285 (actual)
Sponsored by Yale University
Primary completion 2020-02-27
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
285 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
None
Start
2014-02-01
Primary completion
2020-02-27
Eligibility
ALL · 16 Years · 35 Years

Interventions & indications

Drugs
Early Detection (ED)Usual Detection

Sponsors

Yale UniversityLead Sponsor
Harvard UniversityCollaborator
National Institute of Mental Health (NIMH)Collaborator

Investigators

1
Vinod Srihari, MDPrincipal Investigator

Sites

2 total
New Haven, United StatesBoston, United States

Facts & assertions

4 sourced
Enrollment
285
Phase
NA
Primary Completion Date
2020-02-27
Status
COMPLETED
relationships
The graph out of here
drug
Early Detection (ED)
drug
Usual Detection
drug
lead_sponsor
Yale University
company
collaborator
Harvard University
company
National Institute of Mental Health (NIMH)
company
indication
Schizophrenia
indication
Psychosis
indication
Schizophrenia
indication
investigator
Vinod Srihari, MD
person